Publications by Type
252 found
Show per page
Peer-Reviewed Publication Types
Chancellor, Andrew, Constantin, Daniel, Berloffa, Giuliano, Yang, Qinmei, Nosi, Vladimir, Loureiro, José Pedro, Colombo, Rodrigo, Jakob, Roman P., Joss, Daniel, Pfeffer, Michael, De Simone, Giulia, Morabito, Aurelia, Schaefer, Verena, Vacchini, Alessandro, Brunelli, Laura, Montagna, Daniela, Immunity, Online ahead of print. https://doi.org/10.1016/j.immuni.2024.11.019
, Zippelius, Alfred, Davoli, Enrico, et al. (2024). The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells [Journal-article]. Pu, W., Zhu, H., Zhang, M., Pikiolek, M., Ercan, C., Li, J., Huang, X., Han, X., Zhang, Z., Lv, Z., Li, Y., Liu, K., He, L., Liu, X., Heim, M. H., Terracciano, L. M., Tchorz, J. S., & Zhou, B. (2023). Bipotent transitional liver progenitor cells contribute to liver regeneration. Nature Genetics, 55(4), 651–664. https://doi.org/10.1038/s41588-023-01335-9
Borisov, Angel N., Kutz, Alexander, Christ, Emanuel R., Journal of Clinical Endocrinology and Metabolism, 108, 2940–2949. https://doi.org/10.1210/clinem/dgad249
, & Ebrahimi, Fahim. (2023). Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS. Nikolaou, Kostas C., Godbersen, Svenja, Manoharan, Muthiah, Wieland, Stefan, JCI Insight, 8. https://doi.org/10.1172/jci.insight.164694
, & Stoffel, Markus. (2023). Inflammation-induced TRIM21 represses hepatic steatosis by promoting the ubiquitination of lipogenic regulators. Pop, Oltin-Tiberiu, Geng, Anne, Flint, Emilio, Singanayagam, Arjuna, Ercan, Caner, Possamai, Lucia, Patel, Vishal C., Kuenzler, Patrizia, Meier, Marie-Anne, Soysal, Savas, Hruz, Petr, Kollmar, Otto, Tatham, Kate C., Ward, Josie K., Müllhaupt, Beat, Weber, Achim, Wendon, Julia, Niess, Jan Hendrik, Cellular and Molecular Gastroenterology and Hepatology, 16(1), 17–37. https://doi.org/10.1016/j.jcmgh.2023.03.007
, et al. (2023). AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells [Journal-article]. Lett, Martin J, Mehta, Hema, Keogh, Adrian, Jaeger, Tina, Jacquet, Maxime, Powell, Kate, Meier, Marie-Anne, Fofana, Isabel, Melhem, Hassan, Vosbeck, Jürg, Cathomas, Gieri, Heigl, Andres, Gut, 71(12), 2526–2538. https://doi.org/10.1136/gutjnl-2021-324478
, Burri, Emanuel, Mertz, Kirsten D, Niess, Jan Hendrik, Kollmar, Otto, Zech, Christoph J, Ivanek, Robert, et al. (2022). Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells [Journal-article]. Suslov A, Viruses, 14(11). https://doi.org/10.3390/v14112490
, & Wieland S. (2022). Studying Hepatitis Virus-Host Interactions in Patient Liver Biopsies. Ebrahimi F, Semela D, & Hepatology International, 16(4), 817–823. https://doi.org/10.1007/s12072-021-10261-z
. (2022). Impact of propofol sedation on the diagnostic accuracy of hepatic venous pressure gradient measurements in patients with cirrhosis. Donners R, Zaugg C, Gehweiler JE, Boldanova T, Quantitative Imaging in Medicine and Surgery, 12(2), 1186–1197. https://doi.org/10.21037/qims-21-384
, Terracciano LM, & Boll DT. (2022). Computed tomography (CT) and magnetic resonance imaging (MRI) of diffuse liver disease: a multiparametric predictive modelling algorithm can aid categorization of liver parenchyma. Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Molecular Oncology, 16(3), 665–682. https://doi.org/10.1002/1878-0261.13154
, Ng CKY, & Piscuoglio S. (2022). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Ercan, Caner, Coto-Llerena, Mairene, Gallon, John, Fourie, Lana, Marinucci, Mattia, Hess, Gabriel F., Vosbeck, Jürg, Taha-Mehlitz, Stephanie, Boldanova, Tuyana, Meier, Marie-Anne, Tzankov, Alexandar, Matter, Matthias S., Hoffmann, Martin H. K., Di Tommaso, Luca, von Flüe, Markus, Ng, Charlotte K. Y., Communications Medicine, 2. https://doi.org/10.1038/s43856-022-00074-y
, Soysal, Savas D., Terracciano, Luigi M., et al. (2022). Genomic analysis of focal nodular hyperplasia with associated hepatocellular carcinoma unveils its malignant potential: a case report. Lett, Martin J, Mehta, Hema, Keogh, Adrian, Jaeger, Tina, Jacquet, Maxime, Powell, Kate, Meier, Marie-Anne, Fofana, Isabel, Melhem, Hassan, Vosbeck, Jurg, Cathomas, Gieri, Heigl, Andres, Gut, 71, 2526–2538. https://doi.org/10.1136/gutjnl-2021-324478
, Burri, Emanuel, Mertz, Kirsten D, Niess, Jan Hendrik, Kollmar, Otto, Zech, Christoph J, Ivanek, Robert, et al. (2022). Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells. Meier, Marie-Anne, Nuciforo, Sandro, Coto-Llerena, Mairene, Gallon, John, Matter, Matthias S., Ercan, Caner, Vosbeck, Jürg, Terracciano, Luigi M., Soysal, Savas D., Boll, Daniel, Kollmar, Otto, Delaloye, Raphaël, Piscuoglio, Salvatore, & Communications Medicine, 2. https://doi.org/10.1038/s43856-022-00150-3
(2022). Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report. Chen Q., Coto-Llerena M., Suslov A, Teixeira R.D., Fofana I., Nuciforo S, Hofmann M., Thimme R., Hensel N., Lohmann V., Ng C.K.Y., Rosenberger G., Wieland S, & Nature Communications, 12(1), 4882. https://doi.org/10.1038/s41467-021-25218-x
(2021). Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses. Ding L, Sun W., Balaz M, He A, Klug M, Wieland S, Caiazzo R, Raverdy V, Pattou F, Lefebvre P, Lodhi IJ, Staels B., Nature Metabolism, 3(12), 1648–1661. https://doi.org/10.1038/s42255-021-00489-2
, & Wolfrum C. (2021). Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. Boldanova T, Fucile G, Vosshenrich J, Suslov A, Ercan C, Coto-Llerena M, Terracciano LM, Zech CJ, Boll DT, Wieland S, & Cell Reports Medicine, 2(11), 100444. https://doi.org/10.1016/j.xcrm.2021.100444
. (2021). Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization. Meier MA, Meier MA, Calabrese D, Suslov A, Terracciano LM, Journal of Hepatology, 75(4), 840–847. https://doi.org/10.1016/j.jhep.2021.04.051
, & Wieland S. (2021). Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. Vosshenrich J, Zech CJ, Heye T, Boldanova T, Fucile G, Wieland S, European Radiology, 31(6), 4367–4376. https://doi.org/10.1007/s00330-020-07511-3
, & Boll DT. (2021). Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models. Suslov A, Meier MA, Ketterer S, Wang X, Wieland S, & Journal of Hepatology, 74(4), 794–800. https://doi.org/10.1016/j.jhep.2020.11.003
. (2021). Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. Nuciforo S, & JHEP Reports, 3(1), 100198. https://doi.org/10.1016/j.jhepr.2020.100198
. (2021). Organoids to model liver disease. Coto-Llerena M, Lepore M, Spagnuolo J, Di Blasi D, Calabrese D, Suslov A, Bantug G, Duong FH, Terracciano LM, De Libero G, & Life Science Alliance, 4(1). https://doi.org/10.26508/LSA.201900612
. (2021). Interferon lambda 4 can directly activate human CD19+ B cells and CD8+ T cells. Sorrentino G, Rezakhani S, Yildiz E, Nuciforo S, Nature Communications, 11(1), 3416. https://doi.org/10.1038/s41467-020-17161-0
, Lutolf MP, & Schoonjans K. (2020). Mechano-modulatory synthetic niches for liver organoid derivation. Kinast V, Plociennikowska A, Anggakusuma, Bracht T, Todt D, Brown RJP, Boldanova T, Zhang Y, Brüggemann Y, Friesland M, Engelmann M, Vieyres G, Broering R, Vondran FWR, Journal of Hepatology, 73(3), 549–558. https://doi.org/10.1016/j.jhep.2020.03.047
, Sitek B, Bartenschlager R, Pietschmann T, & Steinmann E. (2020). C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. Goossens N, Toso C, & Swiss Medical Weekly, 150(32), w20296. https://doi.org/10.4414/smw.2020.20296
. (2020). Management of hepatocellular carcinoma: SASL expert opinion statement. Tran HTL, Morikawa K, Anggakusuma, Zibi R, Thi VLD, Penin F, PLoS ONE, 15(7 July), e0236447. https://doi.org/10.1371/journal.pone.0236447
, Quadroni M, Pietschmann T, Gouttenoire J, & Moradpour D. (2020). OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. Bertisch, B., Brezzi, M., Negro, F., Müllhaupt, B., Ottiger, C., Künzler-Heule, P., Schmid, P., Giudici, F., Clerc, O., Moriggia, A., Roelens, M., Marinucci, F., Zehnder, C., Moradpour, D., Keiser, O., Kaiser, L., Kaiser, L., Heim, M., Hirsch, H., et al. (2020). Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing? Clinical Infectious Diseases, 70(4), 653–659. https://doi.org/10.1093/cid/ciz270
Brenig R, Pop OT, Triantafyllou E, Geng A, Singanayagam A, Perez-Shibayama C, Besse L, Cupovic J, Künzler P, Boldanova T, Brand S, Semela D, Duong FH, Weston CJ, Ludewig B, Life Science Alliance, 3(1). https://doi.org/10.26508/lsa.201900465
, Wendon J, Antoniades CG, & Bernsmeier C. (2020). Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Di Blasi D., Boldanova T, Mori L, Terracciano L., Cellular and Molecular Gastroenterology and Hepatology, 9(2), 195–218. https://doi.org/10.1016/j.jcmgh.2019.08.004
, & De Libero G. (2020). Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. Roelens, Maroussia, Bertisch, Barbara, Moradpour, Darius, Cerny, Andreas, Semmo, Nasser, Schmid, Patrick, Müllhaupt, Beat, Clerc, Olivier, Semela, David, Junker, Christoph, Negro, Francesco, Keiser, Olivia, Negro, Francesco, Kaiser, Laurent, Open Forum Infectious Diseases, 7. https://doi.org/10.1093/ofid/ofaa308
, Hirsch, Hans, Semmo, Nasser, Suter, Franziska, Moradpour, Darius, et al. (2020). All-cause mortality and causes of death in the swiss hepatitis C cohort study (SCCS). Blumer T., Fofana I., Matter M.S., Wang X, Montazeri H., Calabrese D, Coto-Llerena M., Boldanova T, Nuciforo S, Kancherla V., Tornillo L, Piscuoglio S, Wieland S, Terracciano LM, Ng C.K.Y., & Hepatology Communications, 3(7), 971–986. https://doi.org/10.1002/hep4.1365
. (2019). Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. Wieland SF, & The IFN-λ Pony Express (Patent No. 5). 20(5), Article 5. https://doi.org/10.1038/s41590-019-0362-9
. (2019). Calabrese D, Roma G, Bergling S, Carbone W, Mele V, Nuciforo S, Fofana I, Campana B, Szkolnicka D, Hay DC, Tchorz J, Bouwmeester T, Wieland S, & PloS One, 14(8), e0221762. https://doi.org/10.1371/journal.pone.0221762
. (2019). Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells. Broguiere N, Isenmann L, Hirt C, Ringel T, Placzek S, Cavalli E, Ringnalda F, Villiger L, Züllig R, Lehmann R, Rogler G, Advanced Materials (Deerfield Beach, Fla.), 30(43), e1801621. https://doi.org/10.1002/adma.201801621
, Schüler J, Zenobi-Wong M, & Schwank G. (2018). Growth of Epithelial Organoids in a Defined Hydrogel. Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D’Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Journal of Viral Hepatitis, 25(8), 920–929. https://doi.org/10.1111/jvh.12891
, et al. (2018). Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. Suslov A, Boldanova T, Wang X, Wieland S, & Gastroenterology, 154(6), 1778–1790. https://doi.org/10.1053/j.gastro.2018.01.034
. (2018). Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Allgaier, H.-P., Arnold, C., Baumert, T. F., Becker, G., Geiβler, M., Hafkemeyer, P., Harder, J., Heim, M. H., Huber, R., Kern, W. V., Mohr, L., Moradpour, D., Offensperger, S., Offensperger, W.-B., Spangenberg, H. C., Thimme, R., Walter, E., & Von Weizsäcker, F. (2018). From Molecuar to Natural Medicine Von der molekularen Medizin bis zur Naturheilkunde 1. Deutsche Medizinische Wochenschrift, 143(1), 40–45. https://doi.org/10.1055/s-0043-123263
Gauthiez E, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Liver International : Official Journal of the International Association for the Study of the Liver, 37(10), 1431–1445. https://doi.org/10.1111/liv.13401
, Malinverni R, Moradpour D, Müllhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud PY, & Swiss Hepatitis C Cohort Study. (2017). A systematic review and meta-analysis of HCV clearance. Gauthiez, Emeline, Habfast-Robertson, Ines, Rüeger, Sina, Kutalik, Zoltan, Aubert, Vincent, Berg, Thomas, Cerny, Andreas, Gorgievski, Meri, George, Jacob, Liver International, 37(10), 1431–1445. https://doi.org/10.1111/liv.13401
, Malinverni, Raffaele, Moradpour, Darius, Müllhaupt, Beat, Negro, Francesco, Semela, David, Semmo, Nasser, Villard, Jean, Bibert, Stéphanie, Bochud, Pierre-Yves, & Swiss Hepatitis C. Cohort Study. (2017). A systematic review and meta‐analysis of HCV clearance. Giudici, F., Bertisch, B., Negro, F., Stirnimann, G., Müllhaupt, B., Moradpour, D., Cerny, A., Keiser, O., Kaiser, L., Heim, M., Hirsch, H., Dufour, J.-F., Gorgievski, M., Aubert, V., Siegrist, H. H., Lucchini, G. M., Malinverni, R., Semela, D., Schmid, P., et al. (2016). Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. Journal of Viral Hepatitis, 23(9), 697–707. https://doi.org/10.1111/jvh.12535
Bertisch, Barbara, Giudici, Fabio, Negro, Francesco, Moradpour, Darius, Müllhaupt, Beat, Moriggia, Alberto, Estill, Janne, Keiser, Olivia, Kaiser, Laurent, PLoS ONE, 11. https://doi.org/10.1371/journal.pone.0155464
, Hirsch, Hans, Dufour, Jean-François, Gorgievski, Meri, Aubert, Vincent, Siegrist, Hans H., Cerny, Andreas, Lucchini, Gladys Martinetti, Malinverni, Raffaele, Semela, David, et al. (2016). Characteristics of foreign-born persons in the Swiss hepatitis C cohort study: Implications for screening recommendations. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, PloS one, 9(1), e87488. https://doi.org/10.1371/journal.pone.0087488
, & Beglinger C. (2014). Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. de Bruyn Ouboter, Dirk, Schuster, Thomas B., Shanker, Vijay, Journal of Biomedical Materials Research Part A, 102(4), 1155–1163. https://doi.org/10.1002/jbm.a.34778
, & Meier, Wolfgang. (2014). Multicompartment micelle-structured peptide nanoparticles: a new biocompatible gene- and drug-delivery tool. Shanker V, Trincucci G., Journal of Viral Hepatitis, 20(9), 612–621. https://doi.org/10.1111/jvh.12083
, & Duong HT. (2013). Protein phosphatase 2A impairs IFNα-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation. Praxis, 102(17), 1023–1032. https://doi.org/10.1024/1661-8157/a001400
, & Wertli M. (2013). [Severe hypertriglyceridemia]. Journal of hepatology, 58(3), 564–574. https://doi.org/10.1016/j.jhep.2012.10.005
. (2013). Innate immunity and HCV. Journal of Hepatology, 58(3), 564–574. https://doi.org/10.1016/j.jhep.2012.10.005
(2013). Innate immunity and HCV. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Antiviral therapy, 18(8), 1015–1019. https://doi.org/10.3851/imp2567
, Stern JO, Nehmiz G, Kukolj G, Böcher WO, & Mensa FJ. (2013). Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Zeuzem, Stefan, Asselah, Tarik, Angus, Peter, Zarski, Jean-Pierre, Larrey, Dominique, Müllhaupt, Beat, Gane, Ed, Schuchmann, Marcus, Lohse, Ansgar W, Pol, Stanislas, Bronowicki, Jean-Pierre, Roberts, Stuart, Arasteh, Keikawus, Zoulim, Fabien, Antiviral Therapy, 18(8), 1015–1019. https://doi.org/10.3851/imp2567
, Stern, Jerry O, Nehmiz, Gerhard, Kukolj, George, Böcher, Wulf O, & Mensa, Federico J. (2013). Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1 : SOUND-C1 final results. Manns M.P., Gane E., Rodriguez-Torres M., Stoehr A., Yeh C.-T., Marcellin P., Wiedmann R.T., Hwang P.M., Caro L., Barnard R.J., Lee A.W., Baruch Y., Benhamou Y., Cave M., Davis, Faruqui S., Fried M., Godofsky E., Gschwantler M., et al. (2012). Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. Hepatology, 56(3), 884–893. https://doi.org/10.1002/hep.25743
Dill, Michael T, Makowska, Zuzanna, Duong, Francois H T, Merkofer, Franzisca, Filipowicz, Magdalena, Baumert, Thomas F, Tornillo, Luigi, Terracciano, Luigi, & Gastroenterology, 143(3), 777–786. https://doi.org/10.1053/j.gastro.2012.05.044
. (2012). Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Dill, Michael T, Makowska Z, Duong, Francois H T, Merkofer F, Filipowicz, Magdalena, Baumert, Thomas F, Tornillo L, Terracciano L, & Gastroenterology, 143(3), 777–786. https://doi.org/10.1053/j.gastro.2012.05.044
. (2012). Interferon-γstimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Müllhaupt B, Durand F, Roskams T, Dutkowski P, & Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 17 Suppl 2(12), S14–25. https://doi.org/10.1002/lt.22374
. (2011). Is tumor biopsy necessary? Semela D, & Therapeutische Umschau. Revue Therapeutique, 68(4), 213–217. https://doi.org/10.1024/0040-5930/a000153
. (2011). [Hepatocellular carcinoma]. Muellhaupt, Beat, Durand, Francois, Roskams, Tanja, Dutkowski, Philipp, & Liver Transplantation, 17, S14–S25. https://doi.org/10.1002/lt.22374
. (2011). Is tumor biopsy necessary? Semela, David, & Therapeutische Umschau, 68(4), 213–217. https://doi.org/10.1024/0040-5930/a000153
. (2011). Hepatozelluläres Karzinom. Semela,David, & Ther Umsch, 68(5), 213–217.
. (2011). [Hepatocellular carcinoma]. Sarasin-Filipowicz M., & Future Virology, 5(1), 25–31. https://doi.org/10.2217/fvl.09.67
(2010). Interferon-induced gene expression in chronic hepatitis C. Viruses, 1(3), 1073–1088. https://doi.org/10.3390/v1031073
. (2009). HCV innate immune responses. Bernsmeier C, & Swiss medical weekly, 139(47-48), 678–684. https://doi.org/10.4414/smw.2009.12765
. (2009). Insulin resistance in chronic hepatitis C: mechanisms and clinical relevance. Bernsmeier C., & Swiss Medical Weekly, 139(47-48), 678–684.
(2009). Insulin resistance in chronic hepatitis C: Mechanisms and clinical relevance. Bernsmeier, Christine, & Swiss Medical Weekly : Official Journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology, 139(47-48), 678–684. https://doi.org/smw-12765
. (2009). Insulin resistance in chronic hepatitis C : mechanisms and clinical relevance. Dill,Michael T, Makowska,Zuzanna, Duong,Francois H T, Merkofer,Franzisca, Filipowicz,Magdalena, Baumert,Thomas F, Tornillo,Luigi, Terracciano,Luigi, Gastroenterology, 134(3), 716–726. https://doi.org/10.1053/j.gastro.2007.12.044
, Dong X, Zhang X, Zhang X, Yao Z, Shen Y, Qiang B, Wang Y, & He F. (2008). Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gilgen-Anner Y, Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 99(1), 93–98. https://doi.org/10.1016/s1081-1206(10)60628-x
, Ledermann HP, & Bircher AJ. (2007). Iodide mumps after contrast media imaging: a rare adverse effect to iodine. Sawatzki M, & Praxis, 96(13), 509–511. https://doi.org/10.1024/1661-8157.96.13.509
. (2007). [Delayed upper abdominal pain and tarry stool after transjugular liver biopsy. A 24-old man with hemophilia]. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, & Journal of virology, 81(1), 159–165. https://doi.org/10.1128/jvi.01292-06
. (2007). Inhibition of alpha interferon signaling by hepatitis B virus. Digestion, 75(2-3), 122–123. https://doi.org/10.1159/000104819
, Jacob L, & Beglinger C. (2007). The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A, Vaccine, 24(15), 2781–2789. https://doi.org/10.1016/j.vaccine.2006.01.007
, Bach D, Schroeder M, & Kollaritsch H. (2006). Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Duong,Francois H T, Christen,Verena, Filipowicz,Magdalena, & Hepatology (Baltimore, Md.), 43(4), 796–806. https://doi.org/10.1002/hep.21116
. (2006). S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Duong FH, Christen V, Berke JM, Penna SH, Moradpour D, & Journal of virology, 79(24), 15342–15350. https://doi.org/10.1128/jvi.79.24.15342-15350.2005
. (2005). Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. Schnyder B, Schnyder-Candrian S, Pansky A, Schmitz ML, Cytokine, 31(3), 191–202. https://doi.org/10.1016/j.cyto.2005.02.012
, Ryffel B, & Moser R. (2005). IL-17 reduces TNF-induced Rantes and VCAM-1 expression. Croquelois A, Blindenbacher A, Terracciano L, Wang X, Langer I, Radtke F, & Hepatology (Baltimore, Md.), 41(3), 487–496. https://doi.org/10.1002/hep.20571
. (2005). Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Journal of hepatology, 42(3), 431–433. https://doi.org/10.1016/j.jhep.2004.12.016
. (2005). RIG-I: an essential regulator of virus-induced interferon production. Sadallah, Salima, Journal of Hepatology, 42(1), 150–152. https://doi.org/10.1016/j.jhep.2004.07.027
, Hess, Christoph, Klimkait, Thomas, Battegay, Manuel, & Schifferli, Jürg A. (2005). Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo [4]. Therapeutische Umschau. Revue therapeutique, 61(8), 499–504. https://doi.org/10.1024/0040-5930.61.8.499
. (2004). [Autoimmune hepatitis]. Blanchard C, Durual S, Estienne M, Bouzakri K, Journal of immunology (Baltimore, Md. : 1950), 172(6), 3775–3783. https://doi.org/10.4049/jimmunol.172.6.3775
, Blin N, & Cuber JC. (2004). IL-4 and IL-13 up-regulate intestinal trefoil factor expression: requirement for STAT6 and de novo protein synthesis. Duong FH, Filipowicz M, Tripodi M, La Monica N, & Gastroenterology, 126(1), 263–277. https://doi.org/10.1053/j.gastro.2003.10.076
. (2004). Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Hepatology (Baltimore, Md.), 38(6), 1582–1584. https://doi.org/10.1002/hep.510380632
. (2003). A new survival trick of hepatitis C virus: blocking the activation of interferon regulatory factor-3. Zimmers T.A., Pierce R.H., McKillop I.H., Koniaris L.G., & Hepatology, 38(6), 1590–1591. https://doi.org/10.1016/j.hep.2003.09.021
(2003). Resolving the Role of IL-6 in Liver Regeneration [2] (multiple letters). Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, & Hepatology (Baltimore, Md.), 38(3), 674–682. https://doi.org/10.1053/jhep.2003.50378
. (2003). Interleukin 6 is important for survival after partial hepatectomy in mice. Wiederkehr-Adam M, Ernst P, Müller K, Bieck E, Gombert FO, Ottl J, Graff P, Grossmüller F, & The Journal of biological chemistry, 278(18), 16117–16128. https://doi.org/10.1074/jbc.m300261200
. (2003). Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, & Gastroenterology, 124(5), 1465–1475. https://doi.org/10.1016/s0016-5085(03)00290-7
. (2003). Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Tietz A, The Annals of pharmacotherapy, 37(1), 57–60. https://doi.org/10.1345/aph.1c171
, Eriksson U, Marsch S, Terracciano L, & Krähenbühl S. (2003). Fulminant liver failure associated with clarithromycin. Schnyder B, Schnyder-Candrian S, Panski A, Bömmel H, Biochemical and biophysical research communications, 292(4), 841–847. https://doi.org/10.1006/bbrc.2002.6754
, Duschl A, & Moser R. (2002). Phytochemical inhibition of interleukin-4-activated Stat6 and expression of VCAM-1. Staedele H, Wiesner W, European Radiology, 12(4), 946–947. https://doi.org/10.1007/s003300101101
, & Bongartz G. (2002). Potentially misleading CT findings in fatty liver cirrhosis [1]. Wiesner W, Kocher T, JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR), 85(1), 4–6.
, & Bongartz G. (2002). CT findings in eosinophilic enterocolitis with predominantly serosal and muscular bowel wall infiltration. Moradpour D, Wölk B, Cerny A, Minerva medica, 92(5), 329–339.
, & Blum HE. (2001). Hepatitis C: a concise review. Moradpour D, Cerny A, Swiss medical weekly, 131(21-22), 291–298. https://doi.org/10.4414/smw.2001.06097
, & Blum HE. (2001). Hepatitis C: an update. Donda A, Mori L, Shamshiev A, Carena I, Mottet C, European Journal of Immunology, 30(9), 2593–2603. https://doi.org/10.1002/1521-4141(200009)30:9<2593::aid-immu2593>3.0.co;2-0
, Beglinger C, Grunert F, Rochlitz C, Terracciano L, Jantscheff P, & De Libero G. (2000). Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 32(3), 257–263. https://doi.org/10.1016/s1590-8658(00)80831-2
. (2000). Intracellular signalling and antiviral effects of interferons. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, & International journal of cancer, 85(5), 720–725. https://doi.org/10.1002/(sici)1097-0215(20000301)85:5<720::aid-ijc20>3.0.co;2-o
. (2000). Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Journal of virology, 73(10), 8469–8475. https://doi.org/10.1128/jvi.73.10.8469-8475.1999
, Moradpour D, & Blum HE. (1999). Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. Journal of receptor and signal transduction research, 19(1-4), 75–120. https://doi.org/10.3109/10799899909036638
. (1999). The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. Heuss LT, The Journal of general virology, 79 ( Pt 8), 2007–2012. https://doi.org/10.1099/0022-1317-79-8-2007
, Schultz U, Wissmann D, Offensperger WB, Staeheli P, & Blum HE. (1998). Biological efficacy and signal transduction through STAT proteins of recombinant duck interferon in duck hepatitis B virus infection. Steiger JU, Nickerson PW, Hermle M, Thiel G, & Transplantation, 65(12), 1649–1652. https://doi.org/10.1097/00007890-199806270-00019
. (1998). Interferon-gamma receptor signaling is not required in the effector phase of the alloimmune response. Fasler-Kan E, Pansky A, Wiederkehr M, Battegay M, & European journal of biochemistry, 254(3), 514–519. https://doi.org/10.1046/j.1432-1327.1998.2540514.x
. (1998). Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Feng N, Lugli SM, Schnyder B, Gauchat JF, Graber P, Schlagenhauf E, Schnarr B, Wiederkehr-Adam M, Duschl A, Laboratory investigation; a journal of technical methods and pathology, 78(5), 591–602.
, Lutz RA, & Moser R. (1998). The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the nonsignaling interleukin-13 receptor alpha2. Pansky A, Hildebrand P, European journal of clinical investigation, 28(5), 398–406. https://doi.org/10.1046/j.1365-2362.1998.00300.x
, Eberhard M, Kissel T, & Beglinger C. (1998). Growth effects of alpha-interferon but not of bombesin or angiotensin II are mediated by activation of STAT proteins. European journal of clinical investigation, 27(11), 948–955. https://doi.org/10.1046/j.1365-2362.1997.2100770.x
, Gamboni G, Beglinger C, & Gyr K. (1997). Specific activation of AP-1 but not Stat3 in regenerating liver in mice. Moriggl R, Berchtold S, Friedrich K, Standke GJ, Kammer W, Molecular and cellular biology, 17(7), 3663–3678. https://doi.org/10.1128/mcb.17.7.3663
, Wissler M, Stöcklin E, Gouilleux F, & Groner B. (1997). Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells. Pless M, Norga K, Carroll M, Blood, 89(9), 3175–3185.
, D’Andrea AD, & Mathey-Prevot B. (1997). Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding.